|
|
It has been a year like no other in recent memory for public health. At the U.S. Food and Drug Administration, much of our focus has been dominated by our response to the COVID-19 pandemic. We’ve continued to make important scientific progress, with each day bringing new knowledge and understanding of the SARS-CoV-2 virus and the disease it causes, leading to the issuance of Emergency Use Authorizations (EUA) for two vaccines, and to increased availability of testing and treatment options.
The efforts by FDA staff in response to the virus involved a significant increase in the agency’s workload. But throughout, our workforce continued to make unparalleled contributions and demonstrated unwavering commitment to our many essential public health responsibilities.
|
|
|
|
